Posted on

Lawmakers propose cut in Medicaid rates (Illinois)

The article below has been highlighted and summarized by our research team. It is provided here for member convenience as part of our Curator service.

 
 

 
 

Curator summary

Illinois legislators are beginning the process to take back money from MCOs they perceived as not spent during the pandemic.

 

 
 

 
 

Clipped from: https://www.commercial-news.com/news/lawmakers-propose-cut-in-medicaid-rates/article_cc89c4be-3d6a-11eb-8701-6789aeaaa10d.html

Koehler, Crespo say insurers making excess profits during pandemic

Illinois State Capitol in Springfield 

Capitol News Illinois file photo

SPRINGFIELD – Two Democratic lawmakers this week introduced legislation to reduce state payments to the insurance companies that manage Illinois’ Medicaid program, arguing that the COVID-19 pandemic is resulting in excess profits for the insurers.

Sen. Dave Koehler, of Peoria, and Rep. Fred Crespo, of Hoffman Estates, say that money saved due to the pandemic could be used to help struggling downstate hospitals whose resources have been strained by excess hospitalizations and low revenue.

“While insurance companies and managed care organizations see record-setting profits at the height of a global pandemic, rural communities across the state are experiencing unsustainable strain in their health care systems due to lack of resources,” Koehler said in a statement Wednesday. “The money recouped through this legislation would provide immediate relief for Downstate hospitals that have been devastated by COVID-19.”

The Illinois Medicaid program operates under a “managed care” model in which private insurance companies, known as managed care organizations, or MCOs, are paid a flat rate for managing the care of each Medicaid patient. Their profit margin is the difference between how much they are paid and how much they have to spend reimbursing health care providers for the patients’ care.

Koehler and Crespo argue that patient demand for other, routine, nonemergency medical services like outpatient procedures has plummeted amid the pandemic. In contrast, the insurance companies that manage the program have continued to receive the same per-patient monthly rates for managing the care of each Medicaid recipient, resulting in higher profit margins.

On Wednesday, the two lawmakers filed companion bills in the General Assembly, Senate Bill 4207 and House Bill 5867, which call for reducing the enrollment-based payments by 20 percent for the duration of the COVID-19 disaster declaration.

In addition, the bill would effectively make the reduced rates retroactive by reducing future payments on a prorated basis to claw back a portion of the rates that have already been paid out since the disaster declaration went into effect March 9.

Koehler said Illinois spends roughly $1.7 billion per month for MCO payments, so a 20-percent reduction would reduce that by $340 million.

Because the General Assembly is not currently in session, the bills have not yet been assigned to committees. However, the organization that lobbies for the MCOs has already begun pushing back against the plan, arguing that it’s based on a false premise that utilization rates have actually decreased.

“There were significant decreases in utilization in April and May; however, by July utilization had rebounded,” Samantha Olds Frey, CEO of the Illinois Association of Medicaid Health Plans, said in a statement. “It is important to note that MCOs don’t just pay for hospital visits but a comprehensive healthcare benefit; such as: pharmaceuticals, long term care, and behavioral health. We recognize there may be individual provider partners with decreased utilization, but with the expansion of telehealth and the reinstatement of elective procedures health care utilization has stabilized.”

Koehler said in an interview Friday that he expected resistance from MCOs, but he said he believes the plan has support within the heath care provider industry.

It is unclear if lawmakers will meet again during the 101st General Assembly, which officially ends in January, meaning both bills may need to be refiled during the 102nd General Assembly scheduled to begin Jan. 13.

Capitol News Illinois is a nonprofit, nonpartisan news service covering state government and distributed to more than 400 newspapers statewide. It is funded primarily by the Illinois Press Foundation and the Robert R. McCormick Foundation.

Posted on

Itamar Medical Comments on U.S. Centers for Medicare & Medicaid Services (CMS) 2021 Fee Schedule with Reimbursement Update for Home Sleep Apnea Testing Nasdaq:ITMR

The article below has been highlighted and summarized by our research team. It is provided here for member convenience as part of our Curator service.

 
 

 
 

Curator summary

 

Sleep apnea device payments under Medicare got richer (comparatively) for one device manufacturer than its competitors.

 
 

Clipped from: https://www.globenewswire.com/news-release/2020/12/09/2142686/0/en/Itamar-Medical-Comments-on-U-S-Centers-for-Medicare-Medicaid-Services-CMS-2021-Fee-Schedule-with-Reimbursement-Update-for-Home-Sleep-Apnea-Testing.html

 
 

WatchPAT™ to effectively maintain current reimbursement levels despite broader reduction in conversion rates

CAESAREA, Israel, Dec. 09, 2020 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today commented on the recent release of the 2021 Physician Fee Schedule from the U.S. Centers for Medicare & Medicaid Services (CMS). This Fee Schedule represents the third year of a four-year proposed plan to reevaluate reimbursement in home sleep apnea diagnostic codes. The final changes will become effective on January 1, 2021.
 

The 2021 Fee Schedule further widens the gap between the CPT-95800 used with Itamar Medical’s WatchPATTM device of approximately $163, a -3.5% decrease from 2020, compared to CPT-code 95806 used with competitive Home Sleep Apnea Testing (HSAT) devices of approximately $95, a -20% decrease from 2020.

In the 2021 Fee Schedule, the professional RVUs of both 95800 and 95806 were slightly increased (about 1%), but for the first time in the last three years of adjustments, have CPT 95800 Technical Component RVUs increased by 9.5% while CPT-95806 technical RVUs were significantly reduced (18.8%). In addition to the RVUs, the rates were further impacted by the broader reduction in the CMS conversion factor from 36.09 to 32.41 resulting in the final fee schedule rates.

“The increase in 95800 RVUs will allow providers utilizing our WatchPAT devices to maintain the current reimbursement levels despite the broader reduction in conversion rates, allowing them to continue to diagnose their patients and improve lives,” said Gilad Glick, CEO of Itamar Medical. “The changes to the 2021 Physician Fee Schedule for code 95800 continue the steady trend we have seen since 2017, and we expect to see continued support, thereby expanding the broad use of the WatchPAT device.”

The below table shows the new reimbursement fees for Home Sleep Apnea Testing. For more information about the CMS update, you may visit CMS website:

https://www.cms.gov/medicaremedicare-fee-service-paymentphysicianfeeschedpfs-federal-regulation-notices/cms-1734-f

A 2021 Reimbursement and Coding Guide can be also found on the Itamar Medical website:
 

https://www.itamar-medical.com/watchpat-reimbursement/

About Itamar Medical Ltd.

Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs. The Company’s key product, WatchPAT, is commercially available within major markets including the US, Japan, and Europe. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Statements preceded by, followed by, or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, and similar expressions or future or conditional verbs such as “will”, “should”, “would”, “may” and “could” are generally forward-looking in nature and not historical facts. For example, when we discuss expanding the broad use of the WatchPAT, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of Itamar Medical’s control and actual results, expressed or implied by such forward-looking statements, could differ materially from Itamar Medical’s current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by us in reports filed with, or furnished to, the U.S. Securities and Exchange Commission (“SEC”) and the Israel Securities Authority (“ISA”), including our latest Annual Report on Form 20-F which is on file with the SEC and the ISA. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Itamar Medical Investor Relations Contact (U.S.)

Leigh Salvo or Caroline Paul
Gilmartin Group
Phone: +1-415-937-5412
investors@itamar-medical.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8ceb62fb-085a-4317-bace-c311667cd0a0

 
 

Posted on

Idaho DHW Encourages Idaho Medicaid Providers to Apply For Funding Before December 18 Deadline | Idaho

The article below has been highlighted and summarized by our research team. It is provided here for member convenience as part of our Curator service.

 
 

 
 

Curator summary

Idaho providers that get more than 20% of their revenues from Medicaid can apply for COVID relief funding by December 18.

 
 

 
 

Clipped from: https://www.bigcountrynewsconnection.com/idaho/idaho-dhw-encourages-idaho-medicaid-providers-to-apply-for-funding-before-december-18-deadline/article_8c30eba4-3a40-11eb-bdd8-ab80eeb19f4c.html

 
 

BOISE – Idaho Medicaid providers may be eligible for funding from the Medicaid Provider CFAC Stabilization Funding Opportunity, but the deadline is fast approaching. The one-page application is due by 5:00pm on December 18.

This is an opportunity for providers who are enrolled with Idaho Medicaid to apply for part of the federal funds Idaho received to respond to the COVID-19 pandemic. This is the second round of the funding opportunity and is targeted at Medicaid providers who receive 20% or more of their revenue from Idaho Medicaid.

“A few providers have emailed after receiving their checks, letting us know the funding helps. One provider called it an ‘unexpected blessing.’ We hope to see more applications for more opportunities to provide some relief,” said Matt Wimmer, division administrator for Medicaid, in the Department of Health and Welfare (DHW). “The application, in most cases, will let providers know immediately if they are eligible. All Medicaid providers, but especially the smaller ones, can really benefit from this. But they have to apply.”

Idaho Medicaid providers who meet the following qualifications should apply before December 18. They must be:

  • In-state providers
  • Actively enrolled with Idaho Medicaid
  • In good standing, meaning no current provider actions, sanctions, or debts owed
  • In good standing with the state of Idaho, meaning applicants do not owe any back taxes
  • In good standing with the local, state, and federal government, meaning applicant is not suspended or debarred from receiving federal funds
  • Have Medicaid revenue greater than or equal to 20% of total annual revenues for calendar year 2019

For more information on how to apply: https://coronavirus.idaho.gov/wp-content/uploads/2020/11/IDHW_CFAC.pdf

Posted on

Increased federal funding, decreased use gives Alabama Medicaid $178M carry forward

The article below has been highlighted and summarized by our research team. It is provided here for member convenience as part of our Curator service.

 
 

 
 

Curator summary

Alabama will have a surplus this year because of the combination of federal COVID relief and decreased utilization during the pandemic.

 

 
 

 
 

Clipped from: https://www.wbrc.com/2020/12/07/increased-federal-funding-decreased-use-gives-alabama-medicaid-m-carry-forward/

 
 

AlabamaMedicaid. (Source: Alabama Daily News)

By MARY SELL, Alabama Daily News

Despite record-high enrollment, the Alabama Medicaid Agency expects to have a $178 million carry forward in state funding at the end of this fiscal year.

That’s because of an increase in federal funding since the coronavirus pandemic began and a decrease in the utilization of Medicaid-funded health services as more people stayed home in 2020, Medicaid Commissioner Stephanie Azar told a panel of lawmakers recently.

That carry forward can be used in fiscal 2022.

“We all know we’re still in the throes of the pandemic,” Azar said. “The uncertainty of preparing the 2022 budget is real and difficult.”

Lawmakers will begin in earnest their fiscal 2022 budget planning when the legislative session begins in February. The new budget year begins in October. Subtracting the carry forward, Azar said she’ll be asking for $769 million from the state’s General Fund in 2022. This year’s appropriation was $820 million. Medicaid is the General Fund’s biggest expense.

Separate from the carry forward, Azar is asking lawmakers to allow her to keep a “reserve fund” of about $74 million to cover future COVID-19 caused increases or a drop in federal funding.

Committee member Sen. Jim McClendon, R-Springville, said having the money to apply to next year’s budget because of the additional federal funds is a positive for the state.

“I think the real question is, how long will this last?” McClendon said.

Azar said it’s not yet known how long the additional federal funding will continue, making budgeting difficult. Hence, the proposed reserve fund.

McClendon later said he thought the reserve money was a good idea.

“We’re supposed to plan for the unknown, that’s not possible,” he said.

Prior to COVID-19, the federal government paid about 72% of Alabama Medicaid’s expenses. In response to the pandemic, that amount was increased to about 78%, Azar said. That 6.2% increase was nationwide, but it came with strings attached, she told lawmakers: A requirement that during the declared pandemic, states can’t terminate individuals from Medicaid if they were already enrolled in the program or became enrolled during the emergency period. The only way recipients can now come off of Medicaid is if they die, move out of state or voluntarily remove themselves.

“That usually doesn’t happen,” Azar said.

Medicaid enrollment is now at a record 1.126 million. Up from about 1.05 million prior to the pandemic.

“It’s going up about 10,000 people per month,” Azar said. About 6,000 of those each month are children. Children have always been Alabama Medicaid’s largest consumer group.

Alabama’s restrictions on Medicaid enrollment do not allow for able-bodied adults without children to be on the rolls, so COVID-caused spikes in unemployment don’t translate into large numbers of adults now receiving Medicaid. Azar stressed to lawmakers that the enrollment increases do not equate to Medicaid expansion to cover more poor Alabamians, something advocacy groups have been lobbying for for almost a decade.

Azar also told lawmakers that despite the federal increase, some states have struggled with their Medicaid budgets, particularly states that pay for managed care — they’re paying a third party a set fee no matter how little patients used Medicaid services this year — and states with expanded Medicaid rolls and larger patient populations.

Posted on

Sens. Toomey and Brown propose pregnancy care improvements for Medicaid recipients | News | northcentralpa.com

The article below has been highlighted and summarized by our research team. It is provided here for member convenience as part of our Curator service.

 
 

 
 

Curator summary

National legislation has been introduced to improve pregnancy mortality trends for Medicaid-covered moms.

 
 

Clipped from: https://www.northcentralpa.com/news/sens-toomey-and-brown-propose-pregnancy-care-improvements-for-medicaid-recipients/article_491cdba6-391f-11eb-a59d-b3aa65010e44.html

 
 

Washington, D.C. – In recent years, physicians and researchers have been focusing intensely on preventable pregnancy-related deaths, finding that the leading causes are cardiovascular/coronary conditions, infections, excessive bleeding, pre-eclampsia/eclampsia, and cardiomyopathy. Medicaid financed nearly half of all U.S. births in 2018, and in some states covers over 60% of births.

Records have also shown that pregnant patients on Medicaid have a higher rate of severe maternal morbidity and mortality than those with private health insurance. The statistic is unsurprising; Medicaid beneficiaries are primarily low-income individuals, who experience high rates of chronic illnesses and adverse health challenges. Black women have also been found to experience a disproportionate number of pregnancy-related deaths.

Given Medicaid’s ties to both a large number of births in the U.S. and to populations with a greater likelihood of chronic conditions, Senators Pat Toomey (R-Pa.) and Sherrod Brown (D-Ohio) have teamed up to propose new prenatal care initiatives for Medicaid enrollees.

“Nearly 700 women died last year in the United States as a result of complications from pregnancy and childbirth, but we know that as many as two-thirds of these deaths may be preventable,” said Senator Toomey. “This legislation will help improve health outcomes for pregnant women and mothers enrolled in Medicaid by increasing information and resources to better monitor and treat at-risk pregnancies, as well as inform Congress on policies that may assist states in reducing maternal deaths.”

“A mother’s chance of surviving pregnancy shouldn’t depend on her zip code or the type of insurance she has,” said Brown. “Too many mothers are dying. As the death rate continues to skyrocket, the disparities in maternal mortality have increased along with it, further contributing to the Black maternal health crisis – and that has to change. By meeting moms where they are, listening to health experts, and establishing best practices, we can improve health outcomes and keep more of our mothers and children healthy and safe.”

The proposed legislation, called The Supporting Best Practices for Healthy Moms Act, would:

  • Create a national advisory committee on reducing maternal deaths to:

 
 

  • Establish best practices for Medicaid-covered care providers to screen, monitor, and treat at-risk pregnancies
  • Generate culturally competent materials to inform pregnant patients about potential risks during pregnancy, birth, and postpartum
  • Identify best practices for tracking maternal mortality trends

 
 

  • Report to Congress on payment disincentives or regulatory barriers to the transfer of pregnant patients between facilities before, during, or after birth

A short summary of the bill can be found here. The full version of the bill is available here.

 
 

 
 

 
 

Posted on

Florida finds PBMs are benefiting from a lucrative profit center

Clipped from: https://www.statnews.com/pharmalot/2020/12/09/florida-pbm-pharmacy-medicaid/

 

As states struggle to control the cost of prescription medicines, a new report found pharmacy benefit managers pocketed more than $89 million collected on behalf of the Florida Medicaid program — and the consultants who ran the analysis recommended state officials rework the arrangements.

The report found that PBMs appear to have profited from what is known as spread pricing, which refers to the dispensing fees that these companies pay pharmacies but then bill at a different rate to state Medicaid programs. In this instance, the PBMs working with managed care plans made $8.64 for each Medicaid prescription, which accounted for 9.5% of total plan spending.

Posted on

2020 Estimated Improper Payment Rates for Centers for Medicare & Medicaid Services (CMS) Programs | CMS

The article below has been highlighted and summarized by our research team. It is provided here for member convenience as part of our Curator service.

 
 

 
 

Curator summary

Latest Payment Error Rate report from CMS show Medicaid at 3x Medicare Part C for improper payments.

 
 

Clipped from: https://www.cms.gov/newsroom/fact-sheets/2020-estimated-improper-payment-rates-centers-medicare-medicaid-services-cms-programs

The Payment Integrity Information Act of 2019 requires CMS to periodically review programs it administers, identify programs that may be susceptible to significant improper payments, estimate the amount of improper payments, and report on the improper payment estimates and the Agency’s actions to reduce improper payments in the Department of Health & Human Services (HHS) annual Agency Financial Report (AFR).

The Office of Management and Budget (OMB) has identified Medicare Fee-For-Service (FFS), Medicare Part C, Medicare Part D, Medicaid, and the Children’s Health Insurance Program (CHIP) as at-risk for significant improper payments. CMS utilizes improper payment measurement programs for these programs and continues to address the drivers of improper payment rates through aggressive corrective action plans.

In response to the COVID-19 Public Health Emergency (PHE), CMS exercised its enforcement discretion to adopt a temporary policy to suspend all improper payment-related engagement/communication or data requests to providers and state agencies between March and August. To minimize burden on providers and states, CMS modified some of the improper payment statistical methodologies to be able to timely report rates in the 2020 AFR based on data already collected at the time of the PHE or that providers or states voluntarily submitted. CMS will still meet the statutory national-level precision requirements that the rates are +/- 3 percentage points at a 95% confidence interval.

It is important to note that improper payment rates are not necessarily indicative of, or measures of, fraud. Instead, improper payments are payments that did not meet statutory, regulatory, administrative, or other legally applicable requirements and may be overpayments or underpayments. Additionally, improper payments do not necessarily represent expenses that should not have occurred. For example, current OMB guidance states that when an agency’s review is unable to discern whether a payment was proper as a result of insufficient or missing documentation, this payment should be considered an improper payment. A significant amount of improper payments is due to instances where a lack of documentation or errors in the documentation limits CMS’s ability to verify the payment was paid correctly. However, had the documentation been submitted or properly maintained, then the payments might have been determined to be proper. A smaller proportion of improper payments are payments that should not have been made or should have been made in different amounts and are considered a monetary loss to the government (e.g., medical necessity, incorrect coding, beneficiary ineligible for program or service, and other errors).

 
 

FY 2020 Estimated Improper Payment Rates and Improper Payments (Billions)[1]

 
 

Program

2019 Improper     Payment Rate

2019 Improper  Payments

2020 Improper Payment Rate

2020 Improper Payments

Medicare FFS

7.25%

$28.91

6.27%

$25.74

Medicare Part

C

7.87%

$16.73

6.78%

$16.27

Medicare Part

D

0.75%

$0.61

1.15%

$0.93

Medicaid

14.90%*

$57.36*

21.36%*

$86.49*

CHIP

15.83%*

$2.74*

27.00%*

$4.78*

*Medicaid and CHIP 2020 estimated improper payments are not comparable to years prior to 2019, due to the reintegration of the PERM eligibility component.

  

  

  

  

 
 

Medicare FFS (Part A and Part B)

CMS estimates the Medicare FFS improper payment rate through the Comprehensive Error Rate Testing (CERT) program. Each year, the CERT program reviews a statistically valid stratified random sample of Medicare FFS claims to determine if they were paid properly under Medicare coverage, coding, and payment rules. The reporting period for the Fiscal Year (FY) 2020 Medicare FFS improper payment rate included claims submitted during the 12-month period from July 1, 2018 through June 30, 2019.

The FY 2020 Medicare FFS estimated improper payment rate is 6.27 percent, representing $25.74 billion in improper payments. This compares to the FY 2019 estimated improper payment rate of 7.25 percent, representing $28.91 billion in improper payments. The decrease was driven by reductions in the improper payment rates for home health and skilled nursing facility claims.

Home Health – $5.90 billion decrease in estimated improper payments (2016 to 2020) due to corrective actions such as policy clarification and Targeted Probe and Educate (TPE) for home health agencies.

  • Skilled Nursing Facility – $1.00 billion decrease in estimated improper payments (2019 to 2020) due to a policy change related to the supporting information for physician certification and recertification for skilled nursing facility services and TPE for skilled nursing facility services.

Medicare Part C (Medicare Advantage)

The Part C improper payment estimate measures improper payments resulting from errors in beneficiary risk scores. The primary component of most beneficiary risk scores is based on clinical diagnoses submitted by plans for risk-adjusted payment. If medical records do not support the diagnoses submitted to CMS, the risk scores may be inaccurate and result in payment errors. The Part C estimate is based on medical record reviews conducted annually, where CMS identifies unsupported diagnoses and calculates corrected risk scores. The FY 2020 Part C improper payment data is representative of enrollee data generated from the Calendar Year 2018 payment year.

For FY 2020, the Part C improper payment estimate is 6.78 percent, representing $16.27 billion in improper payments. This represents a decrease from the FY 2019 rate of 7.87 percent, representing $16.73 billion in improper payments, and was driven primarily by Medicare Advantage organizations submitting a greater number of medical records that validated the diagnoses for which they were paid.

Medicare Part D (Prescription Drug Benefit)

The Medicare Part D improper payment estimate measures the payment error related to inaccurately submitted prescription drug event (PDE) data, where the majority of errors for the program exists. CMS measures the inconsistencies between the information reported on PDEs and the supporting documentation submitted by Part D sponsors including prescription record hardcopies (or medication orders, as appropriate), and detailed claims information. The FY 20202020 Part D improper payment data is representative of PDE data generated from the Calendar Year 2018 payment year.

For FY 2020, the Part D improper payment estimate is 1.15 percent, or $0.93 billion in improper payments. This represents an increase from the FY 2019 estimate of 0.75 percent, or $0.61 billion in improper payments.

Medicaid and CHIP

CMS estimates Medicaid and CHIP improper payments through the Payment Error Rate Measurement (PERM) program. The improper payment rates are based on reviews of the FFS, managed care, and eligibility components of Medicaid and CHIP in the year under review. The PERM program uses a 17-state rotational approach to measure the 50 states and the District of Columbia over a three-year period. By this approach, CMS measures each state once every three years and national improper payment rates include findings from the most recent three-year cycle measurements. Each time a cycle of states is measured, CMS utilizes the new findings and removes the respective cycle’s previous findings. The review period for the FY 2020 Medicaid and CHIP improper payment rate included claims submitted from July 1, 2018 through June 30, 2019.

The FY 2020 national Medicaid improper payment rate estimate is 21.36 percent, representing $86.49 billion in improper payments. The FY 2020 national CHIP improper payment rate estimate is 27.00 percent, representing $4.78 billion in improper payments. Factors that led to  these improper payment rates include:

  • One area driving the FY 2020 Medicaid and CHIP improper payment estimate is the continued reintegration of the PERM eligibility component, which was revamped to incorporate the Affordable Care Act requirements in the PERM eligibility reviews.  CMS will complete the review of the remaining 17 states and the District of Columbia under the new eligibility requirements over the next year and establish a baseline in FY 2021 once all states are measured under the new requirements.
  • Based on the measurement of the first two cycles of states, the major drivers of the increased Medicaid and CHIP eligibility improper payments are a result of the following: 
  • Eligibility errors are mostly due to insufficient documentation to affirmatively verify eligibility determinations or non-compliance with eligibility redetermination requirements. The majority of the insufficient documentation errors represent both situations where:
  • The required verification of eligibility data, such as income, was not done at all and
  • There is indication the eligibility verification was initiated but there was no documentation to validate the verification process was completed, and non- compliance with eligibility redetermination requirements. 
  • The CHIP improper payment rate was also driven by claims where the beneficiary was incorrectly determined to be eligible for CHIP, but upon review was determined eligible for Medicaid, mostly related to beneficiary income calculations, household composition, and third party liability coverage.
  • Non-compliance with requirements for provider revalidation of enrollment and rescreening.
  • Continued non-compliance with provider enrollment, screening, and National Provider Identifier requirements.

Supplemental information related to the FY 2020 Medicaid and CHIP improper payment results will be published on CMS’s website – www.cms.gov/PERM – in early 2021.

Exchange Improper Payment Measurement

While a FY 2016 risk assessment concluded that the Advance Payments of the Premium Tax Credit (APTC) program is susceptible to significant improper payments, the program is not yet reporting improper payment estimates for FY 2020.  CMS is committed to implementing an improper payment measurement program as required by PIIA.  As with similar CMS programs, developing an effective and efficient improper payment measurement program requires multiple, time-intensive steps including contractor procurement; developing measurement policies, procedures, and tools; and extensive pilot testing to ensure an accurate improper payment estimate.  CMS will continue to monitor and assess the program for changes and adapt accordingly.  In FYs 2017 through 2020, CMS conducted development and piloting activities for the APTC improper payment measurement program and will continue these activities in FY 2021.  HHS will continue to update its annual AFRs with the measurement program development status until the reporting of the improper payment estimate.

CMS Actions

CMS is committed to reducing improper payments in the Medicare FFS, Medicare Part C, Medicare Part D, Medicaid, and CHIP programs. While we have made some progress on reducing the improper payment rates in Medicare, we are not satisfied and more work needs to be done to achieve increased and consistent reductions in the future by expanding existing initiatives as well as innovative new processes. CMS’s program integrity strategy relies on a multifaceted approach that includes provider enrollment and screening standards, enforcement authorities, and advanced data analytics, such as predictive modeling. This strikes an important balance by preventing improper payments while reducing the administrative burden on legitimate providers and suppliers. For additional information on the improper payment rate estimates and/or the Agency’s actions to mitigate improper payments, please visit https://www.hhs.gov/about/agencies/asfr/finance/financial-policy-library/agency-financial-
reports/index.html

###

 
 

[1] CMS FY 2020 AFR improper payment data reported does not represent payments that occurred during the COVID-19 PHE period but represent claims submitted July 1, 2018 –June 30, 2019 for the Medicare FFS and Medicaid/CHIP improper payment measurement programs and data generated from Calendar Year 2018 for Medicare Parts C and D improper payment programs.

Posted on

Medicaid Fraud Division recovers $45M for MassHealth | Business | berkshireeagle.com

The article below has been highlighted and summarized by our research team. It is provided here for member convenience as part of our Curator service.

 
 

 
 

Curator summary

MA Fraud Unit reported $45M recovered for FY 2020.

 
 

Clipped from: https://www.berkshireeagle.com/business/medicaid-fraud-division-recovers-45m-for-masshealth/article_4f6820fe-238c-11eb-8129-7b69db10f48c.html

BOSTON — The state Attorney General’s Medicaid Fraud Division recently announced that it had recovered more than $45 million for MassHealth during federal fiscal year 2020, which ended Sept. 30.

The division secured 27 civil settlements with various entities, including home health agencies, mental health centers, ambulance providers, and individual doctors and practices. An additional 11 providers and individuals were charged criminally with defrauding MassHealth, and three individuals were charged criminally with abuse, neglect, or financial misappropriation in long-term care facilities.

Posted on

Medical Supply Company Settles Medicare Fraud Claims | San Fernando Valley Business Journal

CA, Fraud

 
 

The article below has been highlighted and summarized by our research team. It is provided here for member convenience as part of our Curator service.

 
 

 
 

Curator summary

CA DME company paid $500k to settle false claims charges by Medicare and Tricare programs.

 
 

 
 

Clipped from: https://www.sfvbj.com/news/2020/nov/05/medical-supply-company-settles-medicare-fraud-clai/

Valley Home Medical Supply Inc. in Canoga Park paid a $565,873 settlement after allegations arose that the company defrauded the federal government’s Medicare and Tricare programs.

According to a statement from the Department of Justice on Wednesday, Valley Home allegedly submitted false claims to the federal health care programs for unnecessary medical supplies and supplies never delivered to patients between July 2006 and May 2013.


The settlement resolved a whistleblower lawsuit filed by former Valley Home employee Kari Kitamura. She will receive $124,492 as a result of the settlement, or 22 percent of the settlement proceeds, the Department of Justice said. Valley Home will also pay Kitamura $80,000 for attorney’s fees.


Kenneth Greenlinger of Oxnard, who was chief executive of the company at the time, pled guilty in 2017 to two counts of health care fraud. Greenlinger served an eight-month federal prison sentence and was ordered to pay more than $1 million in restitution, according to the department said.


Assistant U.S. Attorney Lisa Palombo, a representative of the federal civil fraud section, worked with the Federal Bureau of Investigation and Department of Health and Human services on the case.

Posted on

Wise psychiatrist pleads guilty to federal health care fraud | Crime | timesnews.net

Fraud, TN, Behavioral Health

The article below has been highlighted and summarized by our research team. It is provided here for member convenience as part of our Curator service.

 
 

 
 

Curator summary

TN psychiatrist stole $500k for up-coded and fake office visits.

 
 

 
 

Clipped from: https://www.timesnews.net/news/crime/wise-psychiatrist-pleads-guilty-to-federal-health-care-fraud/article_aa4ce846-1fd2-11eb-9d45-b32478fef758.html

 
 

ABINGDON — A Wise psychiatrist has pleaded guilty to one count of health care fraud in connection with a six-year series of overbilling Medicaid and Medicare.

According to acting Western District U.S. Attorney Daniel P. Bubar, Uzma Ehtesham, 52, pleaded guilty in Abingdon U.S. District Court on Thursday to federal health care fraud after waiving her right to be indicted.

Bubar said that Ehtesham, between 2010 and 2016, billed Virginia Medicare and Medicaid $500,000 in total fraudulent payments for individual patient office visits — more than 50 a day at times — while claiming “extensive, time consuming and costly office visits” while actually seeing patients in groups of two to four in sessions lasting five to six minutes.

Ehtesham, as part of her plea agreement, is required to pay $1 million total in restitution, fines and forfeiture. She is scheduled for a Jan. 28, 2021, sentencing hearing.

The investigation against Ehtesham was conducted by the Virginia Office of the Attorney General’s Medicaid Fraud Control Unit, Norton Police Department, Southwest Virginia Drug Task Force, and Virginia State Police along with various local police departments, Virginia ABC and the Wise County and Norton Commonwealth’s Attorney’s office.